ACE-031 vs CJC-1295 / Ipamorelin Stack
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
ACE-031
Soluble form of activin type IIB receptor (ActRIIB-Fc fusion protein) that acts as a myostatin and activin trap. Blocks the primary signals that limit muscle growth by sequestering myostatin, activin, and related ligands before they reach cell surface receptors. Phase 2 trials in Duchenne muscular dystrophy demonstrated significant lean mass increases.
Full profileCJC-1295 / Ipamorelin Stack
The CJC-1295 (without DAC) and Ipamorelin combination is the most widely researched and community-validated growth hormone secretagogue stack. By pairing a GHRH analog with a selective GHRP, the two peptides act synergistically — producing GH pulses significantly larger than either compound alone, while maintaining a physiological pulse pattern and minimal side effects.
Full profile| ACE-031 | CJC-1295 / Ipamorelin Stack | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | ACVR2B-Fc, ActRIIB-Fc fusion protein | CJC-1295 Ipamorelin, Mod GRF 1-29 Ipamorelin, CJC Ipa stack, CJC-1295 without DAC with Ipamorelin, GHRH GHRP combination |
| Evidence | Investigational (in trials) | FDA-approved |
| Dosing range | 0.3mg/kg–3mg/kg mg/kg, every 2–4 weeks (subcutaneous injection) | 100mcg each–300mcg each mcg, once daily before sleep (or 2–3x daily for more aggressive protocols) |
| Administration | Subcutaneous injection | Subcutaneous injection (both compounds), Administered together in the same injection |
| Key side effects | Nosebleeds (epistaxis — most common reported AE), Telangiectasia (visible small blood vessel dilation), Gum bleeding, Elevated hemoglobin | Water retention (mild, common), Tingling or numbness in hands/feet (transient), Headache (usually first 1–2 weeks), Fatigue or increased sleepiness (often desired at night dose) |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: ACE-031 is investigational (in trials), while CJC-1295 / Ipamorelin Stack is fda-approved.
- Administration: ACE-031 — Subcutaneous injection; CJC-1295 / Ipamorelin Stack — Subcutaneous injection (both compounds), Administered together in the same injection.
- Dosing units differ: ACE-031 is dosed in mg/kg, CJC-1295 / Ipamorelin Stack in mcg — they operate at different scales.
- Frequency: ACE-031 is typically every 2–4 weeks (subcutaneous injection); CJC-1295 / Ipamorelin Stack is once daily before sleep (or 2–3x daily for more aggressive protocols).
How each works
ACE-031
ACE-031 functions as a decoy receptor, binding myostatin, activin A/B, GDF-11, and BMP-9 in circulation before they can activate cellular ActRIIB receptors. In the Duchenne muscular dystrophy Phase 2 trial, ACE-031 produced meaningful lean body mass increases but was halted due to vascular side effects (epistaxis, telangiectasia) requiring dose and safety optimization.
CJC-1295 / Ipamorelin Stack
CJC-1295 without DAC (Mod GRF 1-29) stimulates GHRH receptors on the pituitary, increasing the amplitude of GH pulses. Ipamorelin independently triggers GH release via the ghrelin receptor (GHS-R1a) with high selectivity — minimal cortisol, prolactin, or aldosterone co-elevation. The combination exploits two separate receptor pathways to produce synergistic GH output. Animal and human studies on each compound individually confirm GH and IGF-1 elevation. The combination is extrapolated from mechanistic research and is the most studied protocol in the peptide research community.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.